search
Back to results

Pyridostigmine for the Treatment of Constipation in Parkinson Disease

Primary Purpose

Parkinson Disease, Constipation

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Pyridostigmine Bromide
Sponsored by
University of Vermont Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Parkinson Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age ≥ 18 years Be able to provide signed informed consent Stated ability and willingness to comply with all study procedures Able to take oral medications Females of reproductive potential who are sexually active must be willing to use two of the following highly effective methods of contraception for the duration of study participation and for an additional 28 days after the end of study drug administration: barrier contraception (female condom, diaphragm, cervical cap with/without spermicide), hormonal contraception, or intrauterine device; OR one of the previously mentioned methods AND partner must use barrier contraception (male condom with/without spermicide) Males of reproductive potential who are sexually active must be willing to use the following highly effective methods of contraception for the duration of study participation and for an additional 28 days after the end of study drug administration: barrier contraception (male condom with/without spermicide) AND partner must be postmenopausal, use hormonal contraception, have an intrauterine device, or use barrier contraception (female condom, diaphragm, cervical cap with/without spermicide) Meet United Kingdom Parkinson's Disease Society Brain Bank Criteria: A. Diagnosis of a parkinsonism: Bradykinesia, plus at least one of the following: Muscular rigidity 4-6 Hz resting tremor Postural stability not caused by primary visual, vestibular, cerebellar or proprioceptive dysfunction B. At least three supportive criteria: Unilateral onset of symptoms Rest tremor Progressive symptoms Persistent asymmetry affecting the side of onset most Excellent response to levodopa Severe levodopa-induced chorea Levodopa response for five years or more Clinical course of 10 years or more Fulfill the ROME IV Criteria for Functional Constipation, with a specific requirement that the patient must have three or fewer defecations per week (criterion Ai): Must include two or more of the following: i. Three or fewer defecations per week ii. Straining during > 25% of defecations iii. Lumpy or hard stools in > 25% of defecations iv. Sensation of incomplete evacuation for > 25% of defecations v. Sensation of anorectal obstruction/blockage for > 25% of defecations vi. Manual maneuvers to facilitate > 25% of defecations Loose stools are rarely present without the use of laxatives Insufficient criteria for irritable bowel syndrome Criteria 1-3 must be fulfilled for at least three months with onset of symptoms at least six months prior to diagnosis Exclusion Criteria: Diagnosis of atypical parkinsonism Diagnosis of drug-induced parkinsonism Diagnosis of vascular parkinsonism Known allergy to pyridostigmine bromide or other study drug components Current or recent (within 90 days of enrollment) use of pyridostigmine for any reason History of any bowel surgery History of bladder or bowel obstruction Severe asthma or chronic obstructive pulmonary disease Meet exclusion criteria noted in the UK Parkinson's Disease Society Brain Bank Criteria, at the PI's discretion: A.Exclusion of any of the following: Repeated strokes with stepwise progression of parkinsonian features Repeated head injury Definite encephalitis Oculogyric crises Neuroleptic treatment at onset of symptoms Greater than one affected relative Sustained remission Strictly unilateral features after 3 years Supranuclear gaze palsy Cerebellar signs Early severe autonomic involvement Early severe dementia Babinski sign Cerebral tumor or communicating hydrocephalus Negative response to large doses of levodopa 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure Significant abnormalities on laboratory analysis (complete blood count, comprehensive metabolic panel, thyroid stimulating hormone) conducted at the screening visit or within the three months prior if available for review Significant abnormalities on screening electrocardiogram conducted at the screening visit or within the three months prior if available for review Positive pregnancy test (if female of child-bearing age) Antibiotic use within two weeks prior to enrollment

Sites / Locations

  • University of Vermont Medical CenterRecruiting

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Pyridostigmine Bromide

Arm Description

Open Label

Outcomes

Primary Outcome Measures

Change in number of spontaneous bowel movements per week after the study intervention
Participants will keep a Bowel Movement Journal during the four week Screening Phase, from which the pre-intervention average number of spontaneous bowel movements will be calculated. They will again keep a Bowel Movement Journal for the four weeks of the Treatment Phase, from which the postintervention average number of spontaneous bowel movements will be calculated.

Secondary Outcome Measures

Changes from Baseline to the End of Study Visit in the Gastrointestinal Dysfunction Scale in Parkinson's Disease (GIDS-PD)
The Gastrointestinal Dysfunction Scale in Parkinson's Disease (GIDS-PD) is a PD-specific self-administered scale that evaluates various gastrointestinal symptoms including, but not limited to, constipation, and lifestyle factors that impact symptoms such as diet and physical activity. The GIDS-PD score is broken down into 3 subscores: constipation, bowel irritability, and upper GI. There are 12 items, and each item score is calculated by multiplying the frequency score and the severity score. The total score is calculated by adding the scores of items 1-12. The minimum score is 1 and the maximum score is 108. While the GIDS-PD is typically completed based on symptoms over the past six months, the investigator will ask the participant to consider their symptoms over the past one month.
Changes from Baseline to the End of Study Visit in the Cleveland Clinic Constipation Scoring System (CCCSS)
The Cleveland Clinic Constipation Scoring System (CCCSS) is a 0-30 point self-administered scale comprised of eight variables (i.e., frequency, difficulty, completeness, pain, time, assistance, failure and history) quantifying the degree of constipation. A score of 0 is normal while a score of 30 indicates severe constipation. While the CCCSS is typically completed based on symptoms over the past six months, the investigator will ask the participants to consider their symptoms over the past one month.
Changes from Baseline to the End of Study Visit in the MDS-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I-IV
The MDS sponsored revision of the Unified Parkinson's Disease Rating Sale (MDS-UPDRS) was developed to evaluate various aspects of Parkinson's disease including non-motor and motor experiences of daily living and motor complications. It includes a motor evaluation and characterizes the extent and burden of disease across various populations. The MDS-UPDRS is broken down into 4 parts: Part I (non-motor experiences of daily living), Part II (motor experiences of daily living), Part III (motor examination), and Part IV (motor complications).
Changes from Baseline to the End of Study Visit in the International Parkinson and Movement Disorder Society Non-Motor Rating Scale (MDS-NMS)
The International Parkinson and Movement Disorder Society Non-Motor Rating Scale (MDS-NMS) is a revision of the Non-Motor Symptoms Scale (NMSS) and was developed to improve and refine the assessment of non-motor symptoms in Parkinson's disease (PD). This rater completed assessment measures frequency and severity of 13 non-motor domains, over 52 items and covers a range of key non-motor symptoms both PD and treatment related, and in greater depth, compared with the NMSS. The scale also has a new MDS-NMS Non-Motor Fluctuations (NMF) Subscale to assess changes in non-motor symptoms in relation to the timing of antiparkinsonian medications across 8 domains. The MDS-NMS is a valid and reliable rating scale that measures the burden of non-motor symptoms, including non-motor fluctuations, in PD patients.
Changes from Baseline to the End of Study Visit in the Parkinson's Disease Questionnaire (PDQ-39).
The Parkinson's Disease Questionnaire (PDQ-39) is a self-administered survey assessing difficulties across eight dimensions of health, specifically, mobility, activities of daily living, emotional wellbeing, stigma, social support, cognition, communications and bodily discomfort. Each of 39 items are scored on a scale of 0-4, with higher scores indicating more profound difficulties. The PDQ-39 is completed based on symptoms over the past one month.
Changes from Baseline to the End of Study Visit in Beck Depression Inventory-II (BDI-II)
The Beck Depression Inventory-II (BDI-II) is a self-administered survey assessing the presence and severity of depression. Each of 21 items are scored from 0-3, with higher scores indicating more severe depressive symptoms. The BDI-II is completed based on symptoms over the past two weeks.
Number of adverse events and serious adverse events that occur during the trial
The investigator will monitor for any potential study drug related adverse events. The pyridostigmine bromide package insert does not recommend any routine safety assessments.

Full Information

First Posted
September 12, 2022
Last Updated
June 15, 2023
Sponsor
University of Vermont Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT05603715
Brief Title
Pyridostigmine for the Treatment of Constipation in Parkinson Disease
Official Title
Pyridostigmine for the Treatment of Constipation in Parkinson Disease
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 10, 2022 (Actual)
Primary Completion Date
February 2024 (Anticipated)
Study Completion Date
December 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Vermont Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Constipation is a common and debilitating non-motor symptom of Parkinson disease (PD) that often precedes the onset of classic motor symptoms by decades. There is no standardized algorithm for managing constipation in this patient population, nor are there dedicated treatments. Studies suggest that constipation can affect quality of life to a significant degree, in many cases just as much as motor symptoms. There is an unmet need for effective treatment options for constipation in this patient population. The goal of this study is to determine the efficacy and safety of pyridostigmine as a treatment for chronic constipation in patients with PD.
Detailed Description
This is a 13-15 week open-label, dose escalation trial of pyridostigmine 60-180mg three times a day (TID) for the treatment of constipation in patients with Parkinson disease.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson Disease, Constipation

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
16 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Pyridostigmine Bromide
Arm Type
Other
Arm Description
Open Label
Intervention Type
Drug
Intervention Name(s)
Pyridostigmine Bromide
Intervention Description
Dose escalation trial of Pyridostigmine bromide oral tablets 60-180 mg TID for four weeks
Primary Outcome Measure Information:
Title
Change in number of spontaneous bowel movements per week after the study intervention
Description
Participants will keep a Bowel Movement Journal during the four week Screening Phase, from which the pre-intervention average number of spontaneous bowel movements will be calculated. They will again keep a Bowel Movement Journal for the four weeks of the Treatment Phase, from which the postintervention average number of spontaneous bowel movements will be calculated.
Time Frame
13-15 Weeks
Secondary Outcome Measure Information:
Title
Changes from Baseline to the End of Study Visit in the Gastrointestinal Dysfunction Scale in Parkinson's Disease (GIDS-PD)
Description
The Gastrointestinal Dysfunction Scale in Parkinson's Disease (GIDS-PD) is a PD-specific self-administered scale that evaluates various gastrointestinal symptoms including, but not limited to, constipation, and lifestyle factors that impact symptoms such as diet and physical activity. The GIDS-PD score is broken down into 3 subscores: constipation, bowel irritability, and upper GI. There are 12 items, and each item score is calculated by multiplying the frequency score and the severity score. The total score is calculated by adding the scores of items 1-12. The minimum score is 1 and the maximum score is 108. While the GIDS-PD is typically completed based on symptoms over the past six months, the investigator will ask the participant to consider their symptoms over the past one month.
Time Frame
9-11 Weeks
Title
Changes from Baseline to the End of Study Visit in the Cleveland Clinic Constipation Scoring System (CCCSS)
Description
The Cleveland Clinic Constipation Scoring System (CCCSS) is a 0-30 point self-administered scale comprised of eight variables (i.e., frequency, difficulty, completeness, pain, time, assistance, failure and history) quantifying the degree of constipation. A score of 0 is normal while a score of 30 indicates severe constipation. While the CCCSS is typically completed based on symptoms over the past six months, the investigator will ask the participants to consider their symptoms over the past one month.
Time Frame
9-11 Weeks
Title
Changes from Baseline to the End of Study Visit in the MDS-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I-IV
Description
The MDS sponsored revision of the Unified Parkinson's Disease Rating Sale (MDS-UPDRS) was developed to evaluate various aspects of Parkinson's disease including non-motor and motor experiences of daily living and motor complications. It includes a motor evaluation and characterizes the extent and burden of disease across various populations. The MDS-UPDRS is broken down into 4 parts: Part I (non-motor experiences of daily living), Part II (motor experiences of daily living), Part III (motor examination), and Part IV (motor complications).
Time Frame
9-11 Weeks
Title
Changes from Baseline to the End of Study Visit in the International Parkinson and Movement Disorder Society Non-Motor Rating Scale (MDS-NMS)
Description
The International Parkinson and Movement Disorder Society Non-Motor Rating Scale (MDS-NMS) is a revision of the Non-Motor Symptoms Scale (NMSS) and was developed to improve and refine the assessment of non-motor symptoms in Parkinson's disease (PD). This rater completed assessment measures frequency and severity of 13 non-motor domains, over 52 items and covers a range of key non-motor symptoms both PD and treatment related, and in greater depth, compared with the NMSS. The scale also has a new MDS-NMS Non-Motor Fluctuations (NMF) Subscale to assess changes in non-motor symptoms in relation to the timing of antiparkinsonian medications across 8 domains. The MDS-NMS is a valid and reliable rating scale that measures the burden of non-motor symptoms, including non-motor fluctuations, in PD patients.
Time Frame
9-11 Weeks
Title
Changes from Baseline to the End of Study Visit in the Parkinson's Disease Questionnaire (PDQ-39).
Description
The Parkinson's Disease Questionnaire (PDQ-39) is a self-administered survey assessing difficulties across eight dimensions of health, specifically, mobility, activities of daily living, emotional wellbeing, stigma, social support, cognition, communications and bodily discomfort. Each of 39 items are scored on a scale of 0-4, with higher scores indicating more profound difficulties. The PDQ-39 is completed based on symptoms over the past one month.
Time Frame
9-11 Weeks
Title
Changes from Baseline to the End of Study Visit in Beck Depression Inventory-II (BDI-II)
Description
The Beck Depression Inventory-II (BDI-II) is a self-administered survey assessing the presence and severity of depression. Each of 21 items are scored from 0-3, with higher scores indicating more severe depressive symptoms. The BDI-II is completed based on symptoms over the past two weeks.
Time Frame
9-11 Weeks
Title
Number of adverse events and serious adverse events that occur during the trial
Description
The investigator will monitor for any potential study drug related adverse events. The pyridostigmine bromide package insert does not recommend any routine safety assessments.
Time Frame
13-15 Weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years Be able to provide signed informed consent Stated ability and willingness to comply with all study procedures Able to take oral medications Females of reproductive potential who are sexually active must be willing to use two of the following highly effective methods of contraception for the duration of study participation and for an additional 28 days after the end of study drug administration: barrier contraception (female condom, diaphragm, cervical cap with/without spermicide), hormonal contraception, or intrauterine device; OR one of the previously mentioned methods AND partner must use barrier contraception (male condom with/without spermicide) Males of reproductive potential who are sexually active must be willing to use the following highly effective methods of contraception for the duration of study participation and for an additional 28 days after the end of study drug administration: barrier contraception (male condom with/without spermicide) AND partner must be postmenopausal, use hormonal contraception, have an intrauterine device, or use barrier contraception (female condom, diaphragm, cervical cap with/without spermicide) Meet United Kingdom Parkinson's Disease Society Brain Bank Criteria: A. Diagnosis of a parkinsonism: Bradykinesia, plus at least one of the following: Muscular rigidity 4-6 Hz resting tremor Postural stability not caused by primary visual, vestibular, cerebellar or proprioceptive dysfunction B. At least three supportive criteria: Unilateral onset of symptoms Rest tremor Progressive symptoms Persistent asymmetry affecting the side of onset most Excellent response to levodopa Severe levodopa-induced chorea Levodopa response for five years or more Clinical course of 10 years or more Fulfill the ROME IV Criteria for Functional Constipation, with a specific requirement that the patient must have three or fewer defecations per week (criterion Ai): Must include two or more of the following: i. Three or fewer defecations per week ii. Straining during > 25% of defecations iii. Lumpy or hard stools in > 25% of defecations iv. Sensation of incomplete evacuation for > 25% of defecations v. Sensation of anorectal obstruction/blockage for > 25% of defecations vi. Manual maneuvers to facilitate > 25% of defecations Loose stools are rarely present without the use of laxatives Insufficient criteria for irritable bowel syndrome Criteria 1-3 must be fulfilled for at least three months with onset of symptoms at least six months prior to diagnosis Exclusion Criteria: Diagnosis of atypical parkinsonism Diagnosis of drug-induced parkinsonism Diagnosis of vascular parkinsonism Known allergy to pyridostigmine bromide or other study drug components Current or recent (within 90 days of enrollment) use of pyridostigmine for any reason History of any bowel surgery History of bladder or bowel obstruction Severe asthma or chronic obstructive pulmonary disease Meet exclusion criteria noted in the UK Parkinson's Disease Society Brain Bank Criteria, at the PI's discretion: A.Exclusion of any of the following: Repeated strokes with stepwise progression of parkinsonian features Repeated head injury Definite encephalitis Oculogyric crises Neuroleptic treatment at onset of symptoms Greater than one affected relative Sustained remission Strictly unilateral features after 3 years Supranuclear gaze palsy Cerebellar signs Early severe autonomic involvement Early severe dementia Babinski sign Cerebral tumor or communicating hydrocephalus Negative response to large doses of levodopa 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure Significant abnormalities on laboratory analysis (complete blood count, comprehensive metabolic panel, thyroid stimulating hormone) conducted at the screening visit or within the three months prior if available for review Significant abnormalities on screening electrocardiogram conducted at the screening visit or within the three months prior if available for review Positive pregnancy test (if female of child-bearing age) Antibiotic use within two weeks prior to enrollment
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lisa M Deuel, MD
Phone
(802) 847-4589
Email
Lisa.Deuel@uvmhealth.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lisa M Deuel, MD
Organizational Affiliation
University of Vermont
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Vermont Medical Center
City
Burlington
State/Province
Vermont
ZIP/Postal Code
05401
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Katherine Chan
Phone
802-847-1597
Email
katherine.chan@uvmhealth.org
First Name & Middle Initial & Last Name & Degree
Lisa Deuel, MD

12. IPD Sharing Statement

Learn more about this trial

Pyridostigmine for the Treatment of Constipation in Parkinson Disease

We'll reach out to this number within 24 hrs